Drugs / Cagrilintide B
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07597018 | May 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07184086 | Sep 2025 → Oct 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06797869 | Jan 2025 → Aug 2026 overdue | diabetic polyneuropathy, type 2 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07282613 | Aug 2026 → Sep 2029 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07011667 | Jun 2025 → Mar 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cagrilintide B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07597018 ↗ |
| Route | Subcutaneous | “Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.” NCT06797869 ↗ |